TRACP-5b
Biomarker2 papers1 finding
- Humans1
- Animals1
Interventions
1Romosozumab
downin humans1
1 study
Romosozumab
downin humans1
Romosozumab decreases TRACP-5b in humans (-32.1% vs. -33.1%).
Humansosteoporosissubcutaneous210 mg monthly12 months
Equivalent Twelve-Month Bone Mineral Density Response to Romosozumab in Patients Aged ≥ 85 Years and < 85 Years: A Multi-center Real-World Cohort Study (n = 417) from Northern Japan · Calcified tissue international · 25 Sep 2026
Latest
2MoleculesAnimals
Baicalein reduces disuse-driven skeletal senescence and alters gut microbes in rats
Oral treatment restored bone density and mechanical strength while suppressing inflammatory markers and rebalancing intestinal bacteria in a disuse…Oral treatment restored bone density and mechanical strength while suppressing inflammatory markers and rebalancing intestinal bacteria in a disuse model.